

Prepare for the unpredictable

Risk assessment and early intervention for COVID-19 vaccination centers

At COVID-19 vaccination locations, the importance of patient safety remains central. Care teams need to be ready to address a diverse population with unknown health concerns, while being able to account for any potential adverse reactions to the vaccine. They need to prepare for the unpredictable.

Vaccines can provoke a severe allergic response known as anaphylaxis¹, which can lead to cardiac arrest in some cases.

Having a level of preparedness allows care teams to identify individuals exhibiting signs of distress, and could help lessen the anxiety of those waiting for care.

Care teams need to be able to quickly assess and react to situations on site, which may help to ease the burden for hospitals already overwhelmed by COVID-19 patients.

Through smart solutions, Philips provides the assistance you need to support patient safety during COVID-19 mass vaccination programs. Onsite care teams can then:

- · Assess the immediate health needs of individuals
- Respond to anaphylactic shock and cardiac arrest
- Reassure patients during the post-vaccination observation period.

Support your immediate needs, and the demands of the future

The Philips solution for early intervention and response



Respond

arrest (SCA).



The **Philips EarlyVue VS30** vital signs monitor includes automated Early Warning Scoring (EWS) to help you quickly pinpoint subtle signs of deterioration, and confidently decide on appropriate, proactive care.

The **Philips Heartstart FRx** defibrillator provides intuitive, stepby-step voice instructions, including CPR guidance and an audible metronome. This helps guide basic life support (BLS) responders while

treating a suspected sudden cardiac

Reassure

The Philips IntelliVue X3 portable patient monitor is easy to use, with intuitive smartphone-style operation and a scalable set of clinical measurements for continuous monitoring.

Bundle contents²

Assess

For vaccination centers estimating 1,000 individuals daily

For vaccination centers estimating up to 5,000 individuals daily

EarlyVue VS30 vital signs monitor	1×	3×
HeartStart FRx defibrillator	1×	1×
IntelliVue X3 portable patient monitor	1×	3×

- · 1 month of supplies
- · Clinical instruction short guide and training manual. Additional clinical education programs also available.
- · Pre-configured equipment (ready to use)
- · Standard product warranty

Part of a bigger picture

Any investment you make in patient monitoring solutions to address the COVID-19 pandemic needs to work for the longer term, too. Our solution for early intervention and response includes equipment thoughtfully selected to provide a path to continued value and use, beyond the vaccination period.

Each vaccination center or situation may require a customized approach. Contact your Philips sales representative for help determining the right solution so you can prepare for the unpredictable.

available in your region with the same or similar capabilities.



Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep 2021;70:46–51. DOI: http://dx.doi.org/10.15585/mmwr.mm7002e1 Individual products may not be available in all geographies. Contact your Philips Representative for information on alternative products